Center-Authored Papers

Filters: Author is Rezvani, Andrew R  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract
Flowers MED, Storer BE, Carpenter PA, Rezvani AR, Vigorito AC, Campregher PV, Moravec C, Kiem H-P, Fero ML, Georges GE et al..  2008.  Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(12):1380-4. Abstract
Rezvani AR, Storb R.  2008.  Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.. Journal of autoimmunity. 30(3):172-9. Abstract
Rezvani AR, Storer BE, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey TR, Forman SJ, Lange T et al..  2008.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(2):211-7. Abstract
2011
Rezvani AR, Storer BE, Storb R, Mielcarek M, Maloney DG, Sandmaier BM, Martin PJ, McDonald GB.  2011.  Decreased Serum Albumin as a Biomarker for Severe Acute Graft-vs-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(11):1594-1601. Abstract
Rezvani AR, Maloney DG.  2011.  Rituximab resistance.. Best practice & research. Clinical haematology. 24(2):203-16. Abstract
2012
Rezvani AR, Storb RF.  2012.  Prevention of graft-vs.-host disease.. Expert opinion on pharmacotherapy. 13(12):1737-50. Abstract
Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J, Sandmaier BM, Myerson D, Chauncey TR, Storb R et al..  2012.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.. Blood. 119(11):2657-2664. Abstract
2013
Rezvani AR, McCune JS, Storer BE, Batchelder A, Kida A, Deeg HJ, McDonald GB.  2013.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(7):1033-9. Abstract
Rezvani AR, Sandmaier BM.  2013.  Allogeneic hematopoietic cell transplantation for indolent non-Hodgkin lymphoma: indications and outcomes.. Current opinion in hematology. 20(6):509-14. Abstract
Sato M, Storb R, Loretz C, Stone D, Mielcarek M, Sale GE, Rezvani AR, Graves SS.  2013.  Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.. Transplantation. 96(1):34-41. Abstract
Acute Disease
Rezvani AR, Storer BE, Guthrie KA, Schoch GH, Maloney DG, Sandmaier BM, Storb R.  2015.  Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(1):105-12. Abstract
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract
Adolescent
Flowers MED, Storer BE, Carpenter PA, Rezvani AR, Vigorito AC, Campregher PV, Moravec C, Kiem H-P, Fero ML, Georges GE et al..  2008.  Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(12):1380-4. Abstract
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract
Adoptive Transfer
Rezvani AR, Storb R.  2008.  Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.. Journal of autoimmunity. 30(3):172-9. Abstract
Adult
Flowers MED, Storer BE, Carpenter PA, Rezvani AR, Vigorito AC, Campregher PV, Moravec C, Kiem H-P, Fero ML, Georges GE et al..  2008.  Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(12):1380-4. Abstract
Rezvani AR, Storer BE, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey TR, Forman SJ, Lange T et al..  2008.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(2):211-7. Abstract
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract
Aged
Rezvani AR, Storer BE, Maris M, Sorror ML, Agura E, Maziarz RT, Wade JC, Chauncey TR, Forman SJ, Lange T et al..  2008.  Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(2):211-7. Abstract
Rezvani AR, Norasetthada L, Gooley TA, Sorror ML, Bouvier ME, Sahebi F, Agura E, Chauncey TR, Maziarz RT, Maris M et al..  2008.  Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.. British journal of haematology. 143(3):395-403. Abstract
Rezvani AR, Storer BE, Guthrie KA, Schoch GH, Maloney DG, Sandmaier BM, Storb R.  2015.  Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(1):105-12. Abstract
Flowers MED, Storer BE, Carpenter PA, Rezvani AR, Vigorito AC, Campregher PV, Moravec C, Kiem H-P, Fero ML, Georges GE et al..  2008.  Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(12):1380-4. Abstract
Animals
Rezvani AR, Storb R.  2008.  Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.. Journal of autoimmunity. 30(3):172-9. Abstract
Antibody Development Core Facility
Sato M, Storb R, Loretz C, Stone D, Mielcarek M, Sale GE, Rezvani AR, Graves SS.  2013.  Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.. Transplantation. 96(1):34-41. Abstract